Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.

We found no benefit in continuing Bev treatment beyond progression after first-line treatment containing Bev for patients with advanced NS-NSCLC. Further research of validated predictive biomarkers of response to treatment after long-term antiangiogenic therapy is required.